Affiliations: [a]
Department of Neurology, Layton Aging and Alzheimer’s Disease Center, Oregon Health & Science University, Portland, OR, USA
| [b]
Department of Neurology, Center for Alzheimer’s Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA
| [c]
Vanderbilt University, Nashville, TN, USA
| [d]
Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Correspondence:
[*]
Correspondence to: Kevin Duff, 3181 SW Sam Jackson Park Rd (Maiil code: CR131), Portland, OR 97239, USA. Tel.: +1 503 494 6975; Fax: +1503 494 7499; E-mail: duffk@ohsu.edu.
Abstract: Background:The Quick Dementia Rating System (QDRS) is a brief, informant-reported dementia staging tool that approximates scores on the Clinical Dementia Rating Scale in patients with Alzheimer’s disease (AD). Objective:The current study sought to examine change in the QDRS across time, which is necessary for clinical and research efforts. Methods:One-hundred ten older adults (intact, mild cognitive impairment [MCI], mild AD, classified with Alzheimer’s Disease Neuroimaging Initiative criteria) were rated on the QDRS by an informant and had an amyloid positron emission tomography scan at baseline. The informant re-rated each participant on the QDRS after one year. Dependent t-tests compared the entire sample and various subgroups (e.g., cognitive status, amyloid status) on baseline and follow-up QDRS scores. Results:In the entire sample, the Total score on the QDRS significantly increased (i.e., worsened) on follow-up (p < 0.001). When subgroups were analyzed, the MCI and mild AD subjects showed increasing (i.e., worsening) QDRS Total scores (both p < 0.001), but the intact subjects remained stable over time (p = 0.28). Additionally, those classified as being amyloid positive at baseline showed significantly increased QDRS Total scores at follow-up (p < 0.001) compared to those who were amyloid negative at baseline, whose QDRS Total scores remained stable over time (p = 0.63). Conclusion:The QDRS can potentially demonstrate worsening functioning status across one year, especially in those who have MCI or mild AD and those who are amyloid positive. Therefore, the current results preliminarily suggest that the QDRS may provide an efficient tool for tracking progression in clinical trials in AD.
